Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Sadia Jehan, Whitney E. Zahnd, Nikki R. Wooten & Kristen D. Seay. (2024) Geographic variation in availability of opioid treatment programs across U.S. communities. Journal of Addictive Diseases 42:2, pages 136-146.
Read now
Read now
John J. Mariani, Cale Basaraba, Martina Pavlicova, Daniel M. Alschuler, Daniel J. Brooks, Amy L. Mahony, Christina Brezing, Nasir H. Naqvi & Frances R. Levin. (2023) Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder. The American Journal of Drug and Alcohol Abuse 49:5, pages 618-629.
Read now
Read now
Nicholas Livingston, Xenia Leviyah, Victoria Ameral, Elise Hocking & Christine Timko. (2022) Scoping review of intervention studies to improve opioid and alcohol use outcomes and links to care following inpatient detoxification. Addiction Research & Theory 30:2, pages 134-148.
Read now
Read now
An-Li Wang, Zhenhao Shi, Igor Elman & Daniel D. Langleben. (2020) Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder. The American Journal of Drug and Alcohol Abuse 46:4, pages 472-477.
Read now
Read now
Mohammad Sibai, Kaitlyn Mishlen, Edward V. Nunes, Frances R. Levin, John J. Mariani & Adam Bisaga. (2020) A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. The American Journal of Drug and Alcohol Abuse 46:3, pages 289-296.
Read now
Read now
Richard N Rosenthal & Viral V Goradia. (2017) Advances in the delivery of buprenorphine for opioid dependence. Drug Design, Development and Therapy 11, pages 2493-2505.
Read now
Read now
Evgeny Krupitsky, Edwin Zvartau, Elena Blokhina, Elena Verbitskaya, Valentina Wahlgren, Marina Tsoy-Podosenin, Natalia Bushara, Andrey Burakov, Dmitry Masalov, Tatyana Romanova, Arina Tyurina, Vladimir Palatkin, Tatyana Yaroslavtseva, Anna Pecoraro & George Woody. (2016) Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. The American Journal of Drug and Alcohol Abuse 42:5, pages 614-620.
Read now
Read now
Stacey C. Sigmon, Adam Bisaga, Edward V. Nunes, Patrick G. O'Connor, Thomas Kosten & George Woody. (2012) Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. The American Journal of Drug and Alcohol Abuse 38:3, pages 187-199.
Read now
Read now
Paolo Mannelli, Kathleen S Peindl & Li-Tzy Wu. (2011) Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Substance Abuse and Rehabilitation 2, pages 113-123.
Read now
Read now
Wilfrid Noel Raby, Kenneth M. Carpenter, Jami Rothenberg, Adam C. Brooks, Huiping Jiang, Maria Sullivan, Adam Bisaga, Sandra Comer & Edward V. Nunes. (2009) Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence. American Journal on Addictions 18:4, pages 301-308.
Read now
Read now
Paolo Mannelli, Ashwin A Patkar, Kathleen Peindl, Edward Gottheil, Li-Tzy Wu & David A Gorelick. (2009) Early Outcomes Following Low Dose Naltrexone Enhancement of Opioid Detoxification. American Journal on Addictions 18:2, pages 109-116.
Read now
Read now
Herbert D. Kleber. (2007) Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience 9:4, pages 455-470.
Read now
Read now
Kathleen M. Carroll & Bruce J. Rounsaville. (2007) A Perfect Platform: Combining Contingency Management with Medications for Drug Abuse. The American Journal of Drug and Alcohol Abuse 33:3, pages 343-365.
Read now
Read now
Articles from other publishers (55)
Kevin Wenzel, Julia Thomas, Jennifer Carrano, Jennifer Stidham & Marc Fishman. (2024) A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone. Journal of Substance Use and Addiction Treatment, pages 209366.
Crossref
Crossref
Raka Jain, Piyali Mandal & Sachin Rana. (2024) An efficient LC-QTOF-mass spectrometry method for monitoring naltrexone compliance in urine of opioid-dependent subjects. Journal of Opioid Management 20:1, pages 5-9.
Crossref
Crossref
Medhat M. Bassiony, Nelly R. Abdelfattah, Amany Elshabrawy & Mary M. Adly. (2023) A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. International Clinical Psychopharmacology.
Crossref
Crossref
Virendra V. Singh, Anju Dhawan, Siddhartha Sarkar, Ashwani K. Mishra & Rakesh K. Chadda. (2023) Relapse during opioid use disorder treatment: A pilot study to understand the reasons for opioid use during treatment. Industrial Psychiatry Journal 32:2, pages 361-368.
Crossref
Crossref
Virendra Vikram Singh, Anju DhawanRakesh K. ChaddaAshwani Kumar MishraSiddharth Sarkar. (2022) A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone. Indian Journal of Psychological Medicine 45:1, pages 26-32.
Crossref
Crossref
Pengyue Zhang, Krystel Tossone, Robert Ashmead, Tina Bickert, Emelie Bailey, Nathan J. Doogan, Aimee Mack, Schuyler Schmidt & Andrea E. Bonny. (2022) Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data. Journal of Substance Abuse Treatment 136, pages 108686.
Crossref
Crossref
Victoria Ameral, Elise Hocking, Xenia Leviyah, Noam G. Newberger, Christine Timko & Nicholas Livingston. (2022) Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder. Drug and Alcohol Dependence 233, pages 109379.
Crossref
Crossref
John D. Roache, Martina Pavlicova, Aimee Campbell, Tse‐Hwei Choo, Michelle Peavy, Andrea S. Kermack, Edward V. NunesJrJr & John Rotrosen. (2021) Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research 45:12, pages 2569-2578.
Crossref
Crossref
Marc Fishman, Kevin Wenzel, Jennifer Scodes, Martina Pavlicova, Aimee N. C. Campbell, John Rotrosen & Edward Nunes. (2021) Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. The American Journal on Addictions 30:5, pages 433-444.
Crossref
Crossref
Kara E. Rudolph, Iván Díaz, Nima S. Hejazi, Mark J. van der Laan, Sean X. Luo, Matisyahu Shulman, Aimee Campbell, John Rotrosen & Edward V. Nunes. (2021) Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. Addiction 116:8, pages 2094-2103.
Crossref
Crossref
Kathleen T. Brady, Frances R. Levin, Marc Galanter & Herbert D. KleberMichael Capata & Karen Hartwell. 2021. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment.
Edward V. Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L. Silverman, Sarah C. Akerman & Maria A. Sullivan. (2020)
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes
et al
. (2020): Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism
. Addiction 115:11, pages 2188-2190.
Crossref
Crossref
Elyssa Wiecek, Andrea Torres-Robles, Rachelle Louise Cutler, Shalom Isaac Benrimoj & Victoria Garcia-Cardenas. (2020) Impact of a Multicomponent Digital Therapeutic Mobile App on Medication Adherence in Patients with Chronic Conditions: Retrospective Analysis. Journal of Medical Internet Research 22:8, pages e17834.
Crossref
Crossref
Blair Fisher, Kathryn Witherow & Nathan E. Kruis. (2019)
Book Review: Nancy E. Marion,
Drug Policy and the Criminal Justice System
. Criminal Justice Policy Review 31:5, pages 783-788.
Crossref
Crossref
Edward V. Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L. Silverman, Sarah C. Akerman & Maria A. Sullivan. (2019) Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism. Addiction 115:2, pages 239-246.
Crossref
Crossref
Thomas Julian. (2020) Long-Term Efficacy of Medication-Assisted Treatment of Opioid Addiction: A Systematic Literature Review—Part 2. Topics in Pain Management 35:7, pages 1-10.
Crossref
Crossref
Mirinda Ann Gormley, Courtney T Blondino, DaShaunda D H Taylor, Elizabeth Lowery, James S Clifford, Benjamin Burkart, Whitney C Graves, Elizabeth C Prom-Wormley & Juan Lu. (2020) Assessment of Co-Occurring Substance Use During Opiate Treatment Programs in the United States. Epidemiologic Reviews 42:1, pages 79-102.
Crossref
Crossref
Abigail Zavod, Sarah C. Akerman, Martha M. Snow, Matt Tierney & Maria A. Sullivan. (2018) Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder. Journal of the American Psychiatric Nurses Association 25:4, pages 272-279.
Crossref
Crossref
Kinam ParkAndrew Otte. (2019) Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. Annual Review of Biomedical Engineering 21:1, pages 61-84.
Crossref
Crossref
DOMINIKA LIPOWSKA JAMES & MARYAM JOWZA. (2019) Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction. Clinical Obstetrics & Gynecology 62:1, pages 87-97.
Crossref
Crossref
Peter D. Friedmann, Kelly E. Dunn, Edward V. Nunes & Charles P. O’Brien. (2018) Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. Journal of Substance Abuse Treatment 85, pages 31-33.
Crossref
Crossref
Jake R. Morgan, Bruce R. Schackman, Jared A. Leff, Benjamin P. Linas & Alexander Y. Walley. (2018) Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment 85, pages 90-96.
Crossref
Crossref
Edward V. Nunes, Michael Gordon, Peter D. Friedmann, Marc J. Fishman, Joshua D. Lee, Donna T. Chen, Mei Chen Hu, Tamara Y. Boney, Donna Wilson & Charles P. O'Brien. (2018) Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. Journal of Substance Abuse Treatment 85, pages 49-55.
Crossref
Crossref
E. M. Krupitsky, E. E. Zvartau, E. A. Blokhina, E. V. Verbitskaya, V. Yu. Wahlgren, M. V. Tsoy-podosenin, N. M. Bushara, A. M. Burakov, D. V. Masalov, T. N. Romanova, A. A. Tiurina, V. Ya. Palatkin, T. S. Yaroslavtseva, G. Yu. Sulimov, A. Pecoraro & G. Woody. (2018) Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:1, pages 26.
Crossref
Crossref
Edward V. Nunes, Joshua D Lee, Dominic Sisti, Andrea Segal, Arthur Caplan, Marc Fishman, Genie Bailey, Gregory Brigham, Patricia Novo, Sarah Farkas & John Rotrosen. (2016) Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. Contemporary Clinical Trials 51, pages 34-43.
Crossref
Crossref
Joshua D. Lee, Edward V. Nunes, Patricia Novo MPA, Genie L. Bailey, Gregory S. Brigham, Allan J. Cohen, Marc Fishman, Walter Ling, Robert Lindblad, Dikla Shmueli-Blumberg, Don Stablein, Jeanine May, Dagmar Salazar, David Liu & John Rotrosen. (2016) NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemporary Clinical Trials 50, pages 253-264.
Crossref
Crossref
George E. Woody, Evgeny Krupitsky & Edwin Zvartau. (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. Journal of Neuroimmune Pharmacology 11:3, pages 401-407.
Crossref
Crossref
Elias Dakwar & Edward V. Nunes. (2016) New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. Current Psychiatry Reports 18:7.
Crossref
Crossref
Azarakhsh Mokri, Marek C. Chawarski, Hamidreza Taherinakhost & Richard S. Schottenfeld. (2016) Medical treatments for opioid use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Addiction 111:5, pages 874-882.
Crossref
Crossref
Michael D. Stein, Megan M. Risi, Genie L. Bailey & Bradley J. Anderson. (2016) Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification. Journal of Substance Abuse Treatment 64, pages 44-46.
Crossref
Crossref
Karen Dugosh, Amanda Abraham, Brittany Seymour, Keli McLoyd, Mady Chalk & David Festinger. (2016) A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction. Journal of Addiction Medicine 10:2, pages 93-103.
Crossref
Crossref
Adam Bisaga, Maria A. Sullivan, Andrew Glass, Kaitlyn Mishlen, Martina Pavlicova, Margaret Haney, Wilfrid N. Raby, Frances R. Levin, Kenneth M. Carpenter, John J. Mariani & Edward V. Nunes. (2015) The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug and Alcohol Dependence 154, pages 38-45.
Crossref
Crossref
Shujun Pan, Haifeng Jiang, Jiang Du, Hanhui Chen, Zhibin Li, Walter Ling & Min Zhao. (2015) Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial. PLOS ONE 10:6, pages e0127598.
Crossref
Crossref
Shanthi Mogali, Nabil A. Khan, Esther S. Drill, Martina Pavlicova, Maria A. Sullivan, Edward Nunes & Adam Bisaga. (2015) Baseline characteristics of patients predicting suitability for rapid naltrexone induction. The American Journal on Addictions 24:3, pages 258-264.
Crossref
Crossref
Wilfrid Noel Raby, John J. Mariani, Frances R. Levin & Edward V. Nunes. 2015. Psychiatry. Psychiatry
2331
2360
.
Maria A. Sullivan, Adam Bisaga, Andrew Glass, Kaitlyn Mishlen, Martina Pavlicova, Kenneth M. Carpenter, John J. Mariani, Frances R. Levin & Edward V. Nunes. (2015) Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug and Alcohol Dependence 147, pages 122-129.
Crossref
Crossref
Louisa Degenhardt, Sarah Larney, Jo Kimber, Michael Farrell & Wayne Hall. (2014)
Excess mortality among opioid‐using patients treated with oral naltrexone in
A
ustralia
. Drug and Alcohol Review 34:1, pages 90-96.
Crossref
Crossref
Janet C. Liu, Joseph D. Ma, Candis M. Morello, Rabia S. Atayee & Brookie M. Best. (2014) Naltrexone Metabolism and Concomitant Drug Concentrations in Chronic Pain Patients. Journal of Analytical Toxicology 38:4, pages 212-217.
Crossref
Crossref
Emmanuel Streel, Christie Chenut, Constentin Papageorgiou & Paul Verbanck. (2014) DSM IV Axis II traits can influence compliance to treatment with oral naltrexone: A preliminary study on 30 opiate dependent patients. Addictive Behaviors 39:1, pages 321-324.
Crossref
Crossref
Gillinder Bedi, Ziva D. Cooper & Margaret Haney. (2013) Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addiction Biology 18:5, pages 872-881.
Crossref
Crossref
De-Xiang Li, Xin-Ying Zhuang, Yi-Ping Zhang, Hao Guo, Ze Wang, Qing Zhang, Yue-Mei Feng & Yong-Gang Yao. (2013) Effects of Tai Chi on the Protracted Abstinence Syndrome: A Time Trial Analysis. The American Journal of Chinese Medicine 41:01, pages 43-57.
Crossref
Crossref
Anthony DeFulio & Kenneth Silverman. (2012) The use of incentives to reinforce medication adherence. Preventive Medicine 55, pages S86-S94.
Crossref
Crossref
Matt Hickman, Louisa Degenhardt, Michael Farrell & Wayne Hall. (2012)
Commentary on
K
elty &
H
ulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?
. Addiction 107:10, pages 1825-1826.
Crossref
Crossref
Nancy M. Petry, Carla J. Rash, Shannon Byrne, Shehryar Ashraf & William B. White. (2012) Financial Reinforcers for Improving Medication Adherence: Findings from a Meta-analysis. The American Journal of Medicine 125:9, pages 888-896.
Crossref
Crossref
Zubair A. Chaudhry, Javaid Sultan & Farrukh Alam. (2018) Predictors for retention in treatment with a UK community-based naltrexone programme for opioid dependence. The Psychiatrist 36:6, pages 218-224.
Crossref
Crossref
Louis A. Pagliaro & Ann Marie Pagliaro. 2011. Handbook of Child and Adolescent Drug and Substance Abuse. Handbook of Child and Adolescent Drug and Substance Abuse
371
453
.
Evgeny Krupitsky, Edward V Nunes, Walter Ling, Ari Illeperuma, David R Gastfriend & Bernard L Silverman. (2011) Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. The Lancet 377:9776, pages 1506-1513.
Crossref
Crossref
Silvia Minozzi, Laura Amato, Simona Vecchi, Marina Davoli, Ursula Kirchmayer & Annette Verster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Kimberly L. KjomeF. Gerard Moeller. (2011) Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence. Substance Abuse: Research and Treatment 5, pages SART.S5452.
Crossref
Crossref
Adam C. Brooks, Deanna Ryder, Deni Carise & Kimberly C. Kirby. (2010) Feasibility and effectiveness of computer-based therapy in community treatment. Journal of Substance Abuse Treatment 39:3, pages 227-235.
Crossref
Crossref
Evgeny Krupitsky, Edwin Zvartau & George Woody. (2010) Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available. Current Psychiatry Reports 12:5, pages 448-453.
Crossref
Crossref
Jennifer C. Veilleux, Peter J. Colvin, Jennifer Anderson, Catherine York & Adrienne J. Heinz. (2010) A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clinical Psychology Review 30:2, pages 155-166.
Crossref
Crossref
Warren K. Bickel & Richard Yi. 2008. Neuroeconomics. Neuroeconomics
289
309
.
Richard J. Bodnar. (2007) Endogenous opiates and behavior: 2006. Peptides 28:12, pages 2435-2513.
Crossref
Crossref
Maria A. Sullivan, Fatima Garawi, Adam Bisaga, Sandra D. Comer, Kenneth Carpenter, Wilfrid N. Raby, Stephen J. Anen, Adam C. Brooks, Huiping Jiang, Evaristo Akerele & Edward V. Nunes. (2007) Management of relapse in naltrexone maintenance for heroin dependence. Drug and Alcohol Dependence 91:2-3, pages 289-292.
Crossref
Crossref